Azenta to Divest B Medical, Refocuses on Sample Management and Multiomics

B Medical divestiture reshapes Azenta’s operating profile

Azenta reports that the results of B Medical Systems are treated as discontinued operations after the company announces a definitive agreement to sell the business, with the transaction expected to close on or before March 31, 2026. The move narrows Azenta’s operational focus to its core life‑sciences offerings—Sample Management Solutions and Multiomics—by removing the vaccine and cold‑chain equipment business from continuing operations. Accounting for B Medical as discontinued operations changes comparability versus prior periods and simplifies ongoing reporting as the company completes the sale process.

The divestiture materially alters the composition of revenue and margins in the quarter ending December 31, 2025, with continuing operations generating $149.0 million in revenue, down 7% sequentially but up 1% year‑over‑year on the narrower basis. Organic growth is negative 1%, reflecting mixed demand across Azenta’s core segments. Management treats the sale as a near‑term strategic repositioning rather than an operational setback, emphasizing concentration on laboratory automation, sample storage and multiomics platforms that support life‑sciences research and biopharma customers.

Removing B Medical from continuing operations also highlights pressure on profitability in the core businesses. Adjusted EBITDA from continuing operations falls to $13.0 million, down 39% sequentially and 21% year‑over‑year, as the company absorbs lower sequential revenue and cost dynamics. Reported diluted earnings per share from continuing operations are $(0.11), versus $1.12 in the prior quarter and $(0.16) a year earlier, while total diluted EPS is $(0.34). Azenta reports non‑GAAP diluted EPS from continuing operations of $0.09, down from $0.21 in the prior quarter.

Segment performance overview

By segment, Sample Management Solutions posts $81.0 million, down 5% sequentially and flat year‑over‑year, while Multiomics records $67.0 million, down 8% sequentially but up 1% from a year earlier. The pattern signals more stable demand in sample management and modest growth in multiomics services and products even as sequential headwinds persist.

Financial context and next steps

Azenta notes that the B Medical sale will be treated as discontinued operations for the reported period and expects to complete the transaction by the end of March 2026. The company’s near‑term financial trajectory depends on closing the divestiture and its ability to restore sequential revenue and margin trends in its remaining life‑sciences businesses.